A subcortico-cortical cholinergic system is affected in Parkinson's disease
References (22)
Neurotransmitter related enzymes in senile dementia of the Alzheimer type
Brain Research
(1979)- et al.
The nucleus basalis magnocellularis: the origin of a cholinergic projection to the neocortex of the rat
Neuroscience
(1980) - et al.
Protein measurement with the Folin phenol reagent
J. biol. Chem.
(1951) - et al.
Acetylcholinesterase-rich projections from the basal forebrain of the rhesus monkey to neocortex
Brain Research
(1976) - et al.
The substantia innominata in Alzheimer's disease: an histochemical and biochemical study of cholinergic marker enzymes
Neurosci. Lett.
(1982) - et al.
Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia
Brain Research
(1982) - et al.
Neocortical cholinergic neurons in elderly people
Lancet
(1977) - et al.
Alzheimer's disease: correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalites
J. Neurol. Sci.
(1982) - et al.
Parkinson disease, dementia and Alzheimer disease: clinico-pathological correlations
Ann. Neurol.
(1980) - et al.
Confusion, dementia and anticholinergics in Parkinson disease
J. Neurol. Neurosurg. Psychiatr.
(1982)
Dementia in Parkinson disease: a neuropathologic study
Neurology
Cited by (151)
Noradrenergic and cholinergic systems take centre stage in neuropsychiatric diseases of ageing
2023, Neuroscience and Biobehavioral ReviewsCompensatory dopaminergic-cholinergic interactions in conflict processing: Evidence from patients with Parkinson's disease
2019, NeuroImageCitation Excerpt :The heterogeneity of neuromodulator system decline in Parkinson's disease (PD) may make it particularly instructive. In addition to the dopaminergic declines that define the disorder, Parkinson's patients often have degeneration along other neural pathways (cholinergic, noradrenergic, serotonergic, etc.; Dunois et al., 1983; Gaspar et al., 1991; Halliday et al., 1990; Kuhls et al., 1996; Rommelfanger and Weinshenker, 2007; Scatton et al., 1983; Stern et al., 1984). There are large individual differences in the degree of degeneration in these other pathways, and those differences can be relatively independent of each other and of the degree of dopaminergic decline (e.g., Bohnen and Albin, 2011; Dunois et al., 1983; Hall et al., 2014; Monchi et al., 2016; Müller and Bohnen, 2013; Perry et al., 1985; Pillon et al., 1989).
G protein-coupled receptors in neurodegenerative diseases
2019, GPCRs: Structure, Function, and Drug DiscoveryImaging the Nonmotor Symptoms in Parkinson's Disease
2017, International Review of NeurobiologyCitation Excerpt :Although the authors did not use a uniform cognitive assessment, a correlation between striatal dopaminergic deficits and cognitive impairment was a common finding (Duchesne et al., 2002; Muller et al., 2000; Pellecchia et al., 2015). The pathophysiology of cognitive impairment may also encompass cholinergic dysfunction within the brainstem and corticostriatal pathway, as initially demonstrated by postmortem studies which reported a profound reduction of cytosolic enzyme choline acetyltransferase (ChAT) in the substantia nigra pars compacta, hippocampus, and especially in the neocortex of PD patients with and without dementia (Dubois, Ruberg, Javoy-Agid, Ploska, & Agid, 1983; Lange, Wells, Jenner, & Marsden, 1993; Ruberg, Ploska, Javoy-Agid, & Agid, 1982). Molecular imaging techniques including PET and SPECT employing radioligands selectively targeting the cholinergic system have led to significant strides in our knowledge of the pathophysiology of cognitive impairment and dementia (Roy et al., 2016).
In situ monitoring of myenteric neuron activity using acetylcholinesterase-modified AlGaN/GaN solution-gate field-effect transistors
2016, Biosensors and Bioelectronics